Genomic stratification beyond Ras/B‐Raf in colorectal liver metastasis patients treated with hepatic arterial infusion

Resection of colorectal liver metastases (CLM) can cure disease, but many patients with extensive disease cannot be fully resected and others recur following surgery. Hepatic arterial infusion (HAI) chemotherapy can convert extensive liver disease to a resectable state or decrease recurrence risk, but response varies and no biomarkers currently exist to identify patients most likely to benefit.

[1]  Lik Hang Lee,et al.  SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance , 2018, Clinical Cancer Research.

[2]  P. Lønning,et al.  Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer , 2018, JAMA surgery.

[3]  J. Vauthey,et al.  SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. , 2018, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[4]  Steven J. M. Jones,et al.  Oncogenic Signaling Pathways in The Cancer Genome Atlas. , 2018, Cell.

[5]  Leah M Chase,et al.  Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma. , 2018, Cancer discovery.

[6]  Ahmet Zehir,et al.  Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. , 2017, JCO precision oncology.

[7]  O. Lichtarge,et al.  Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases , 2017, Annals of surgery.

[8]  Moriah H Nissan,et al.  OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.

[9]  M. Gönen,et al.  Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[11]  C. Sander,et al.  3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets , 2017, Genome Medicine.

[12]  M. Delorenzi,et al.  Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer , 2016, Clinical Cancer Research.

[13]  M. D'Angelica,et al.  Updated long‐term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy , 2016, Journal of surgical oncology.

[14]  N. Socci,et al.  Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity , 2015, Nature Biotechnology.

[15]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[16]  R. Pai,et al.  Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer , 2015, Journal of Clinical Pathology.

[17]  M. D'Angelica,et al.  Surgical management of hepatic metastases of colorectal cancer. , 2015, Hematology/oncology clinics of North America.

[18]  M. D'Angelica,et al.  KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases , 2014, Cancer.

[19]  K. Søreide,et al.  KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection? , 2014, Cancer.

[20]  M. Ladanyi,et al.  BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer , 2014, Cancer.

[21]  Kai Ye,et al.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..

[22]  Steven A. Curley,et al.  RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases , 2013, Annals of surgery.

[23]  J. Massagué.  TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[24]  K. Schulmann,et al.  Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group. , 2011, Clinical colorectal cancer.

[25]  M. Gönen,et al.  Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. , 2010, Journal of the American College of Surgeons.

[26]  L. Schwartz,et al.  Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Silvia Benvenuti,et al.  Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. , 2005, The Lancet. Oncology.

[28]  M. Gonen,et al.  Hepatic arterial infusion after liver resection. , 2005, The New England journal of medicine.

[29]  L H Blumgart,et al.  Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. , 1999, The New England journal of medicine.

[30]  N. Kemeny,et al.  A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer , 1992, Cancer.

[31]  N. Geller,et al.  Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. , 1987, Annals of internal medicine.

[32]  M. Gönen,et al.  Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. , 2018, Annals of surgery.

[33]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[34]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[35]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.